ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 561,13
1,09%
Dow Jones
39 169,52
0,13%
DAX
18 290,66
0,31%
Brent Oil
86,67
0,16%
Bitcoin
62 828,80
-0,03%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Landos Biopharma Inc (LABP)

  7. Landos Biopharma Inc (LABP) Actualités

LABP

Landos Biopharma (LABP)

Landos Biopharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LABP
DateHeureSourceTitreSymboleSociété
03/06/202412h04Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:LABPLandos Biopharma Inc
23/05/202423h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LABPLandos Biopharma Inc
23/05/202422h52Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:LABPLandos Biopharma Inc
23/05/202422h49Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:LABPLandos Biopharma Inc
23/05/202422h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LABPLandos Biopharma Inc
23/05/202422h05PR Newswire (US)AbbVie Completes Acquisition of Landos BiopharmaNASDAQ:LABPLandos Biopharma Inc
09/05/202414h32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LABPLandos Biopharma Inc
25/03/202413h31PR Newswire (US)AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNASDAQ:LABPLandos Biopharma Inc
14/02/202422h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LABPLandos Biopharma Inc
01/06/202322h20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:LABPLandos Biopharma Inc
25/05/202322h20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LABPLandos Biopharma Inc
24/05/202323h58Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LABPLandos Biopharma Inc
12/05/202314h48Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LABPLandos Biopharma Inc
19/04/202314h06Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:LABPLandos Biopharma Inc
19/04/202314h01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LABPLandos Biopharma Inc
30/03/202323h28Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LABPLandos Biopharma Inc
23/03/202313h58Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:LABPLandos Biopharma Inc
23/03/202313h31Edgar (US Regulatory)Annual Report (10-k)NASDAQ:LABPLandos Biopharma Inc
28/02/202323h00GlobeNewswire Inc.Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ FounderNASDAQ:LABPLandos Biopharma Inc
14/02/202323h26Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:LABPLandos Biopharma Inc
11/01/202313h00GlobeNewswire Inc.Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis OrganizationNASDAQ:LABPLandos Biopharma Inc
05/01/202313h05GlobeNewswire Inc.Landos Biopharma Provides Comprehensive Update on Clinical Development PlansNASDAQ:LABPLandos Biopharma Inc
05/01/202313h00GlobeNewswire Inc.Landos Biopharma Announces $16.7 Million Private Placement FinancingNASDAQ:LABPLandos Biopharma Inc
14/11/202204h56TipRanksSVB Securities Sticks to Its Hold Rating for Landos Biopharma (LABP)NASDAQ:LABPLandos Biopharma Inc
11/11/202200h05TipRanksLandos Biopharma (LABP) Receives a Hold from JonesTradingNASDAQ:LABPLandos Biopharma Inc
10/11/202214h00GlobeNewswire Inc.Landos Biopharma Reports Third Quarter 2022 Results and Provides Business UpdateNASDAQ:LABPLandos Biopharma Inc
06/09/202213h00GlobeNewswire Inc.Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical OfficerNASDAQ:LABPLandos Biopharma Inc
16/08/202212h08Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LABPLandos Biopharma Inc
12/08/202214h36TipRanksSVB Securities Keeps Their Hold Rating on Landos Biopharma (LABP)NASDAQ:LABPLandos Biopharma Inc
11/08/202214h30GlobeNewswire Inc.Landos Biopharma Reports Second Quarter 2022 Results and Provides Business UpdateNASDAQ:LABPLandos Biopharma Inc
 Showing the most relevant articles for your search:NASDAQ:LABP

Dernières Valeurs Consultées

COIN
BTCUSD
Bitcoin
NYSE
JPM
JP Morgan Chase
EU
BNP
BNP Paribas
NYSE
KO
Coca Cola
NYSE
MRK
Merck
EU
AI
Air Liquide
NASDAQ
AMZN
Amazon.com
EU
ML
Michelin
SPI
SP500
S&P 500
EU
BEL20
Bel 20
USI
USTECH100
US Tech 100
EU
PX1
CAC 40
EU
LR
Legrand
NYSE
MCD
McDonalds
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés